Clinical Trial: Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Randomized Multicentric Phase III Trial Comparing Simple Surgery to Surgery Plus HIPEC (Hyperthermic Intraperitoneal Chemotherapy) With MMC in Colorectal Patients Who Have a High Risk of Developing Co

Brief Summary: Multicentric randomised trial. The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to decrease the rate of peritoneal carcinomatosis(PC) in patients with high risk of developing PC of colorectal cancer. The safety of this treatment will also be studied.

Detailed Summary: Hyperthermic intraperitoneal chemotherapy(HIPEC) is a recently validated option for the treatment of peritoneal carcinomatosis from colorectal or ovarian origin. This therapeutic program demonstrated a significant improvement of overall survival of the disease. It is not yet known whether surgery followed by HIPEC is effective on decreasing the rate of peritoneal carcinomatosis(PC) in patients with high risk of developing PC of colorectal cancer.Patients with a high risk of developing colorectal Peritoneal Carcinomatosis (PC), defined by Colorectal Cancer With a Resected Minimal Synchronous PC or Ovarian Metastases, or identified T4 by intraoperative pathological diagnosis, or Tumour Rupture in the Abdominal Cavity. If patients with a high risk of developing PC identified by preoperative examination, they will be informed and will sign the consent. After complete resection of their tumor, they will be randomised to surveillance alone (control group) or HIPEC (experimental group). All patients will receive the current standard postoperative adjuvant treatment : 6 months of systemic chemotherapy (currently including FOLFOX4, mFOLFOX6, CapeOx or Capecitabine regimen which could be modified if the standard is modified). Then a work-up is done to find recurrence. If the recurrence occurs, the patient will be treated with the best known treatment.
Sponsor: Zhejiang University

Current Primary Outcome: Disease-free survival [ Time Frame: Three years from the date of randomization ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • 3 year overall survival [ Time Frame: 3 years ]
  • Peritoneal disease-free survival [ Time Frame: 3 years ]
  • 5 year overall survival [ Time Frame: 5 years ]
  • Toxicity [ Time Frame: Baseline before any treatment,3 months post operation, 1 year post operation ]

    Toxicity induced by HIPEC using the NCI CTC criteria; one month and six months morbidity.

    Subgroup analysis: pT4; pts. ≤ 40yrs.

  • Quality of life [ Time Frame: Baseline before any treatment,3 months post operation, 1 year post operation ]
    Duration of operation; return of bowel function; length of hospital stay; return to normal activity; six months and one year QOL, using the SF-36 v1.0; percentage of patients in both arms completing the scheduled postoperative chemotherapy; Subgroup analysis: pT4; pts. ≤ 40yrs.


Original Secondary Outcome: Same as current

Information By: Zhejiang University

Dates:
Date Received: June 21, 2014
Date Started: October 2014
Date Completion: October 2023
Last Updated: April 4, 2017
Last Verified: June 2016